261 related articles for article (PubMed ID: 24067381)
1. Update in inclusion body myositis.
Machado P; Brady S; Hanna MG
Curr Opin Rheumatol; 2013 Nov; 25(6):763-71. PubMed ID: 24067381
[TBL] [Abstract][Full Text] [Related]
2. Sporadic inclusion body myositis: new insights and potential therapy.
Machado PM; Dimachkie MM; Barohn RJ
Curr Opin Neurol; 2014 Oct; 27(5):591-8. PubMed ID: 25159931
[TBL] [Abstract][Full Text] [Related]
3. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
Schmidt K; Schmidt J
Curr Opin Rheumatol; 2017 Nov; 29(6):632-638. PubMed ID: 28832349
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
[TBL] [Abstract][Full Text] [Related]
5. Inclusion Body Myositis.
Goyal NA
Continuum (Minneap Minn); 2022 Dec; 28(6):1663-1677. PubMed ID: 36537974
[TBL] [Abstract][Full Text] [Related]
6. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ
Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931
[TBL] [Abstract][Full Text] [Related]
7. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
Larman HB; Salajegheh M; Nazareno R; Lam T; Sauld J; Steen H; Kong SW; Pinkus JL; Amato AA; Elledge SJ; Greenberg SA
Ann Neurol; 2013 Mar; 73(3):408-18. PubMed ID: 23596012
[TBL] [Abstract][Full Text] [Related]
8. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.
Greenberg SA
Muscle Nerve; 2014 Oct; 50(4):488-92. PubMed ID: 24752512
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
Ikenaga C; Findlay AR; Goyal NA; Robinson S; Cauchi J; Hussain Y; Wang LH; Kershen JC; Beson BA; Wallendorf M; Bucelli RC; Mozaffar T; Pestronk A; Weihl CC
Ann Clin Transl Neurol; 2021 Mar; 8(3):571-578. PubMed ID: 33556224
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW
Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928
[TBL] [Abstract][Full Text] [Related]
12. Significance of Sjögren's syndrome and anti-cN1A antibody in myositis patients.
Levy D; Nespola B; Giannini M; Felten R; Severac F; Varoquier C; Rinagel M; Korganow AS; Martin T; Poindron V; Maurier F; Chereih H; Bouldoires B; Hervier B; Lenormand C; Chatelus E; Geny B; Sibilia J; Arnaud L; Gottenberg JE; Meyer A
Rheumatology (Oxford); 2022 Feb; 61(2):756-763. PubMed ID: 33974078
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and therapy of inclusion body myositis.
Greenberg SA
Curr Opin Neurol; 2012 Oct; 25(5):630-9. PubMed ID: 22941263
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.
Salam S; Dimachkie MM; Hanna MG; Machado PM
Clin Exp Rheumatol; 2022 Feb; 40(2):384-393. PubMed ID: 35225226
[TBL] [Abstract][Full Text] [Related]
15. Advances in the early diagnosis and therapy of inclusion body myositis.
Lilleker JB
Curr Opin Rheumatol; 2018 Nov; 30(6):644-649. PubMed ID: 30074510
[TBL] [Abstract][Full Text] [Related]
16. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
[TBL] [Abstract][Full Text] [Related]
17. Inclusion body myositis: evolving concepts.
Perez-Rosendahl M; Mozaffar T
Curr Opin Neurol; 2022 Oct; 35(5):604-610. PubMed ID: 36069417
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
Mavroudis I; Knights M; Petridis F; Chatzikonstantinou S; Karantali E; Kazis D
J Clin Neuromuscul Dis; 2021 Sep; 23(1):31-38. PubMed ID: 34431799
[TBL] [Abstract][Full Text] [Related]
19. Inclusion Body Myositis.
Greenberg SA
Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1871-1888. PubMed ID: 27922498
[TBL] [Abstract][Full Text] [Related]
20. Inclusion body myositis: clinical features and pathogenesis.
Greenberg SA
Nat Rev Rheumatol; 2019 May; 15(5):257-272. PubMed ID: 30837708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
